Brand-brand Competition Not Likely to Decrease List Prices of Drugs

by Ramya Rachamanti on  July 31, 2019 at 5:40 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Brand-brand competition unlikely to lower list prices of brand-name drugs in the US, according to a study published in the journal PLOS Medicine by Ameet Sarpatwari of Brigham and Women's Hospital and Harvard Medical School, and colleagues.
Brand-brand Competition Not Likely to Decrease List Prices of Drugs
Brand-brand Competition Not Likely to Decrease List Prices of Drugs

US prescription drug spending has increased sharply over the last decade, with higher launch prices of new brand-name drugs and routine price increases on older brand-name drugs. Promoting greater brand-brand competition, which occurs between brand-name drugs indicated for the same condition, has been proposed to address high drug prices.

Show Full Article


Yet many examples exist of price increases following the introduction of brand-name competition, casting doubt on its effectiveness in the pharmaceutical market. To better understand the economic impact of brand-brand competition, Sarpatwari and colleagues systematically reviewed the peer-reviewed literature for studies of how new drug market entry affects prices of drugs within the same class for patients with the same indications.

They searched PubMed and EconLit for original studies on brand-brand competition in the US market published in English between 1990 and April 2019, and found 10 studies evaluating a wide range of drug classes.

None of the 10 studies found that brand-brand competition lowered the list price of existing brand-name drugs within a class. The findings of two studies suggested that such competition may help restrain how new drug prices are set, however.

Other studies found evidence that brand-brand competition was mediated by the relative quality of competing drugs and the extent to which they are marketed, with safer or more effective new drugs and greater marketing associated with higher intra-class list prices.

According to the authors, the findings suggest that policies to promote brand-brand competition in the US pharmaceutical market, such as accelerating approval of non-first-in-class drugs, will probably not result in lower drug list prices in the absence of additional structural reforms.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Drugs Banned in India Neck Cracking 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive